Activated T cells and cytokine-induced CD3+CD56+ killer cells.
Over the past two decades, attempts have been made to develop immunotherapy for patients with cancer. A significant obstacle to the development of successful adoptive immunotherapy has been the availability of appropriate cytotoxic cells. Immunologic effector cells such as lymphokine-activated killer (LAK) cells, activated T cells such as tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer (CIK) cells may be suitable to remove residual tumor cells.
Schmidt-Wolf
G D
GD
Department of Medicine, Virchow Clinic of Humboldt University, Berlin, Germany.
Negrin
R S
RS
Schmidt-Wolf
I G
IG
D017252:CD3 Complex / Q000032:analysis*; D019002:CD56 Antigen / Q000032:analysis*; D006801:Humans; D015979:Killer Cells, Lymphokine-Activated / Q000502:physiology*; D007694:Killer Cells, Natural / Q000276:immunology*
D017252:CD3 Complex; D019002:CD56 Antigen